Recap: Eagle Pharmaceuticals Q2 Earnings

 

Shares of Eagle Pharmaceuticals EGRX were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share were up 63.16% year over year to $0.93, which beat the estimate of $0.80.

Revenue of $48,124,000 up by 14.75% from the same period last year, which beat the estimate of $45,860,000.

Looking Ahead

Eagle Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 09, 2021

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2F&eventid=3193109&sessionid=1&key=7208F077049E6300CE513B89AE3B5830&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $53.43

Company's 52-week low was at $36.48

Price action over last quarter: Up 15.29%

Company Description

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!